Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Pluvia's Fist.com - Pluvia's Plays & Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: semi_infinite who wrote (978)	9/12/2000 5:21:18 PM
From: Pluvia	Respond to of 1766

1. why did Roche fund manufacturing facilities despite the uncertainties? Roche is handling the Phase III trials, without drugs they can't do the trials. None of that has anything to do with the fact that Phase II study designs were flawed. 2. why would the FDA let trms proceed with phase III without clarifying the phase II issues that you described? I expect this to be resolved in Phase III. As a result I expect Phase III results to be worse not better than Phase II results. This is because Phase II results included benefit from the other cocktail of anti-HIV drugs used.